Canada’s Drug Agency (CDA-AMC) recommends that Opdivo in combination with Yervoy be reimbursed by public drug plans for the first-line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer, if certain conditions are met.
